Describe the substance before debating the marketing term
FDA describes ibutamoren as stimulating growth hormone release. That pharmacological action is different from supplying ordinary food protein or a required micronutrient. Informal labels such as natty do not establish regulatory status or a clinical benefit. [1]
FDA’s warning followed laboratory detection of undeclared ibutamoren in a product marketed for children’s growth. The example demonstrates why the stated product category cannot be relied on to establish actual composition. [1]
A hormonal effect is not a safety endpoint
FDA lists potential effects including increased appetite, fluid retention, fatigue, muscle pain and changes in glucose metabolism or insulin sensitivity. It also identifies potential congestive heart failure risk in some individuals and uncertainty about long-term effects. [1]
A claim that a substance raises a hormone does not establish beneficial growth, safe muscle gain or suitability for self-treatment. Combining it with other performance products introduces additional uncertainty. The warning does not provide a safe consumer dosing protocol. [1]
A familiar acronym is not a clearance
Imagine a seller describes MK-677 as a natural research supplement. Those words do not change the identity of ibutamoren or demonstrate FDA approval, verified contents or established safety for the buyer.
| Detail | Implication |
|---|---|
| MK-677 | Ibutamoren |
| Hormone release | Pharmacological action |
| Natural claim | No safety or approval proof |
Sources for this article
- FDA: Hidden ibutamoren in Agebox iKids Growth Day Formula
Source consulted: 2026-09-17. This is a reference resource, not a claim that we conducted the studies or tested a product.